InMode Ltd. (NASDAQ:INMD) Receives Average Recommendation of “Hold” from Analysts

Shares of InMode Ltd. (NASDAQ:INMD) have received an average rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $16.80.

Several research firms have commented on INMD. Robert W. Baird set a $17.00 target price on shares of InMode in a research report on Wednesday, February 11th. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a report on Thursday, January 22nd. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research note on Monday, January 26th. Finally, Canaccord Genuity Group set a $15.00 price objective on shares of InMode and gave the stock a “hold” rating in a report on Wednesday, December 17th.

Institutional Trading of InMode

Large investors have recently made changes to their positions in the stock. Leonteq Securities AG acquired a new position in shares of InMode during the 4th quarter valued at about $26,000. Quadrant Capital Group LLC lifted its holdings in InMode by 127.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after purchasing an additional 1,091 shares during the last quarter. Advisory Services Network LLC acquired a new stake in InMode in the 3rd quarter worth approximately $37,000. Basepoint Wealth LLC bought a new stake in InMode during the fourth quarter worth approximately $39,000. Finally, Blue Trust Inc. boosted its position in InMode by 93.7% during the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock worth $43,000 after purchasing an additional 1,384 shares during the period. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

INMD opened at $13.45 on Thursday. InMode has a fifty-two week low of $12.72 and a fifty-two week high of $19.09. The business has a 50-day moving average of $14.28 and a 200-day moving average of $14.60. The company has a market capitalization of $852.19 million, a PE ratio of 9.34 and a beta of 2.18.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.42 by $0.04. InMode had a return on equity of 14.52% and a net margin of 25.33%.The business had revenue of $103.85 million during the quarter, compared to analysts’ expectations of $104.64 million. During the same quarter in the previous year, the business posted $0.42 EPS. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, equities research analysts expect that InMode will post 1.75 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.